EPIC Proteomics Study Links Prediagnostic Blood Proteins to Prostate Cancer Risk Over 15 Years

Oxford researchers measured circulating proteins in 982 men who later developed prostate cancer and 1,573 controls from the EPIC cohort, with median 16-year follow-up. They detected associations with immune proteins such as GZMK, cell-adhesion molecules, angiogenesis factors, and products of established driver genes including ERBB3 and KRAS. These signals appeared well before any clinical detection, pointing to biological divergence years in advance of diagnosis. The study cross-checked results against other large cohorts and genetic datasets, confirming several but not all protein links. Seven proteins tracked with aggressive, metastatic, or fatal cancers. Absolute risk differences were not reported, leaving clinical effect sizes unclear, and the design cannot distinguish true precursors from undetected microscopic disease at blood draw. Context from prior genetic and PSA studies shows these protein changes may reflect impaired immune surveillance or early vascular remodeling rather than overt malignancy. This extends GWAS findings on pathways but shares their limitation of observational confounding and lack of time-varying exposure data. Next steps require replication in diverse populations, integration with polygenic scores for risk models, and eventual trials testing whether modulating implicated pathways reduces aggressive incidence.